Vertex Pharmaceuticals (VRTX) Long-Term Deferred Tax (2017 - 2026)

Vertex Pharmaceuticals' Long-Term Deferred Tax history runs 10 years deep, the most recent figure standing at $2.9 billion for Q1 2026.

• On a quarterly basis, Long-Term Deferred Tax rose 15.86% year-over-year to $2.9 billion in Q1 2026; TTM through Mar 2026 was $2.9 billion, a 15.86% increase from a year earlier, with the FY2025 full-year figure at $2.9 billion, up 24.31% from the prior year.
• Long-Term Deferred Tax rose to $2.9 billion in Q1 2026 per VRTX's latest filing, from $2.9 billion in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $2.9 billion in Q1 2026 and bottomed at $945.5 million in Q1 2022.
• The 5-year median for Long-Term Deferred Tax is $2.0 billion (2024), against an average of $2.0 billion.
• Across the five-year window, Long-Term Deferred Tax jumped 48.71% in 2023 and advanced 15.86% in 2026, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $1.2 billion in 2022, then surged by 45.33% to $1.8 billion in 2023, then advanced by 28.64% to $2.3 billion in 2024, then advanced by 24.31% to $2.9 billion in 2025, then rose by 1.72% to $2.9 billion in 2026.
• Per Business Quant, the three latest VRTX Long-Term Deferred Tax figures stand at $2.9 billion (Q1 2026), $2.9 billion (Q4 2025), and $2.9 billion (Q3 2025).